Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 7;9(11):1222.
doi: 10.3390/nu9111222.

Nutritional Therapies in Congenital Disorders of Glycosylation (CDG)

Peter Witters  1   2 , David Cassiman  3 , Eva Morava  4   5   6
Affiliations
Review

Nutritional Therapies in Congenital Disorders of Glycosylation (CDG)

Peter Witters et al. Nutrients. .

Abstract

Congenital disorders of glycosylation (CDG) are a group of more than 130 inborn errors of metabolism affecting N-linked, O-linked protein and lipid-linked glycosylation. The phenotype in CDG patients includes frequent liver involvement, especially the disorders belonging to the N-linked protein glycosylation group. There are only a few treatable CDG. Mannose-Phosphate Isomerase (MPI)-CDG was the first treatable CDG by high dose mannose supplements. Recently, with the successful use of d-galactose in Phosphoglucomutase 1 (PGM1)-CDG, other CDG types have been trialed on galactose and with an increasing number of potential nutritional therapies. Current mini review focuses on therapies in glycosylation disorders affecting liver function and dietary intervention in general in N-linked glycosylation disorders. We also emphasize now the importance of early screening for CDG in patients with mild hepatopathy but also in cholestasis.

Keywords: congenital disorders of glycosylation (CDG); diet; galactose; glycosylation; mannose; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Jaeken J., Peanne R. What is new in CDG? J. Inherit. Metab. Dis. 2017;40:569–586. doi: 10.1007/s10545-017-0050-6. - DOI - PubMed
    1. Marques-da-Silva D., Dos Reis Ferreira V., Monticelli M., Janeiro P., Videira P.A., Witters P., Jaeken J., Cassiman D. Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature. J. Inherit. Metab. Dis. 2017;40:195–207. doi: 10.1007/s10545-016-0012-4. - DOI - PubMed
    1. Witters P., Morava E. Congenital disorders of glycosylation (CDG): Review. eLS. 2016:1–6. doi: 10.1002/9780470015902.a0026783. - DOI
    1. Jaeken J., Hennet T., Matthijs G., Freeze H.H. CDG nomenclature: Time for a change! Biochim. Biophys. Acta. 2009;1792:825–826. doi: 10.1016/j.bbadis.2009.08.005. - DOI - PMC - PubMed
    1. Morelle W., Potelle S., Witters P., Wong S., Climer L., Lupashin V., Matthijs G., Gadomski T., Jaeken J., Cassiman D., et al. Galactose supplementation in patients with tmem165-CDG rescues the glycosylation defects. J. Clin. Endocrinol. Metab. 2017;102:1375–1386. doi: 10.1210/jc.2016-3443. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources